이스라엘 - 히브리어 - Ministry of Health

teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

이스라엘 - 히브리어 - Ministry of Health

teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

이스라엘 - 히브리어 - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - solution for inhalation - salbutamol as sulfate 5 mg/ml - selective beta-2 adrenoreceptor agonists - treatment of severe acute asthma (status asthmaticus) and other forms of bronchospasm.

이스라엘 - 히브리어 - Ministry of Health

ferring pharmaceuticals ltd - citric acid anhydrous; magnesium oxide; sodium picosulfate - אבקה להכנת תמיסה - citric acid anhydrous 12 g; magnesium oxide 3.5 g; sodium picosulfate 10 mg - sodium picosulfate, combinations

이스라엘 - 히브리어 - Ministry of Health

teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel

이스라엘 - 히브리어 - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

이스라엘 - 히브리어 - Ministry of Health

padagis israel pharmaceuticals ltd, israel - clotrimazole; dexamethasone acetate; neomycin sulfate - קרם - clotrimazole 1 %; neomycin sulfate 0.645 %; dexamethasone acetate 0.044 % - combinations - combinations - treatment of dermatitis involving also a bacterial and/or fungal infection.

이스라엘 - 히브리어 - Ministry of Health

padagis israel pharmaceuticals ltd, israel - gentamicin sulfate; prednisolone - קרם - prednisolone 0.5 %; gentamicin sulfate 0.16 % - prednisolone and antibiotics - prednisolone and antibiotics - for the treatment of skin inflammation associated with bacterial infection.

이스라엘 - 히브리어 - Ministry of Health

taro pharmaceutical industries ltd - gramicidin; neomycin as sulfate; nystatin; triamcinolone acetonide - משחה - triamcinolone acetonide 1 mg/g; neomycin as sulfate 2.5 mg/g; gramicidin 0.25 mg/g; nystatin 100000 iu/g - triamcinolone and antibiotics - triamcinolone and antibiotics - antifungal, antibacterial

이스라엘 - 히브리어 - Ministry of Health

taro pharmaceutical industries ltd - gramicidin; neomycin as sulfate; nystatin; triamcinolone acetonide - קרם - nystatin 100000 iu/g; gramicidin 0.25 mg/g; neomycin as sulfate 2.5 mg/g; triamcinolone acetonide 1 mg/g - triamcinolone and antibiotics - triamcinolone and antibiotics - for local treatment of skin inflammations accompanied with mycotic and/or bacterial infection.